SM-276001|cas:473930-22-2|西域试剂

SM-276001,99.71%

产品编号：Bellancom-123291| CAS NO：473930-22-2| 分子式：C₁₆H₂₁N₇O| 分子量：327.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-123291	￥3500.00	杭州北京（现货）
Bellancom-123291	￥5800.00	杭州北京（现货）
Bellancom-123291	￥16500.00	杭州北京（现货）
Bellancom-123291	￥24500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SM-276001

产品介绍

SM-276001 是一种有效的选择性 TLR7 激动剂，可以诱导抗肿瘤免疫反应。SM-276001 是一种具有口服活性的干扰素 (IFN) 诱导剂。

生物活性

SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer.

体外研究

SM-276001 (1 nM-10 μM) dose-dependently activates NF-κB through human TLR7.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SM-276001 demonstrates potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice.
Oral administration of SM-276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells.
SM-276001 (3 mg/kg PO biweekly) significantly inhibits tumor growth in the Renca renal cell cancer and CT26 colorectal models.
SM-276001 (orally; 0.1, 1 or 10 mg/kg) leads to the activation of a diverse population of spleen-resident immune effector cells in Balb/c and C57BL/6J mice. When administered at 1 mg/kg or greater, the plasma concentration of SM-276001 exceeds the MEC of 30 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 and B6C3F1 mice bearing Renca or CT26 tumors
Dosage:	3 mg/kg
Administration:	Oral administration twice weekly for 25 days
Result:	Significantly reduced disease burden in mice bearing either Renca or CT26 tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 and B6C3F1 mice bearing Renca or CT26 tumors
Dosage:	3 mg/kg
Administration:	Oral administration twice weekly for 25 days
Result:	Significantly reduced disease burden in mice bearing either Renca or CT26 tumors.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (381.82 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0546 mL	15.2728 mL	30.5455 mL
5 mM	0.6109 mL	3.0546 mL	6.1091 mL
10 mM	0.3055 mL	1.5273 mL	3.0546 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.35 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.35 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.35 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.35 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。